PTPN3 is a potential immune checkpoint inhibitor target that may mediate T cells, while PTPN5 and PTPN7 can specifically inactivate MAPKs, so the developed inhibitors may have therapeutic potential for treating neurodegenerative diseases in AML patients19,20. The gene discussed is PTPN5; the disease is neurodegenerative disease.